BeyondSpring sells majority stake in China unit Bulin to Biolin to fund DUBLIN-4 trial
BeyondSpring will sell its China unit Bulin, which it indirectly owns a majority stake in, to Biolin Investment in non-cash consideration funding DUBLIN-4 development in China covering about 221 patients.